<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:00 – 12:15 p.m. | Welcome & Why We’re Here  
  - Luke Rosen, Co-Founder & Board Chair – KIF1A.ORG  
  - Kathryn Atchley, President – KIF1A.ORG |
| 12:15 – 12:45 p.m. | Let’s Connect: Ice Breaker |
| 12:45 – 12:55 p.m. | We Remember  
  - Anouk Lanouette Turgeon, Lhassa’s mom – KIF1A.ORG Advocate |
| 1:00 – 1:45 p.m. | KIF1A.ORG’s Therapeutic Development Strategy  
  - Dominique Lessard, PhD, Chief Science Officer – KIF1A.ORG  
  - Hans Christinger, MBA, Board Member – KIF1A.ORG  
  - Kathryn Atchley, President – KIF1A.ORG |
| 1:45 – 2:45 p.m. | What We’ve Learned from the KAND Natural History Study  
  - Wendy Chung, MD, PhD, Chief of Clinical Genetics Division in Pediatrics & Principal Investigator – Columbia University Irving Medical Center  
  - Lia Boyle, MD, PhD Candidate, Researcher, Chung Lab – Columbia University Irving Medical Center |
| 2:45 – 3:00 p.m. | Break & Networking |
| 3:00 – 4:15 p.m. | **Family Track**  
  Patient Perspectives Activity  
  - Small breakout groups led by KAND patient advocates to discuss what matters most to KAND families  
**Scientist & Clinician Track**  
  Short Talks  
  - Michael Silverman, PhD, Principal Investigator & Troy Collins, PhD Student & Lab Member, Silverman Lab – Simon Fraser University  
  - Ajay Chitnis, MBBS, PhD, Senior Investigator & Head of Section on Neural Developmental Dynamics – National Institutes of Health, Division of Intramural Research  
  - Jayne Aiken, PhD, Postdoctoral Scientist, Holzbaur Lab – Perelman School of Medicine, University of Pennsylvania  
  - Douglas Chapnick, PhD, CEO & Founder – BioLoomics |
| 4:15 – 4:45 p.m. | What Matters Most to KAND Families?  
  - Alejandro Duval, Avantika Fraser, Charisma Freeman, Audrey Guilmatre, Charlotte Klinepeter, Ennio Lamari, Kassondra Lambert, Joshua Metz, Megan Rockwell, & Maribel Saez – KIF1A Patient and Family Community Members  
  - Moderated by: Kathryn Atchley, President – KIF1A.ORG |
| 4:45 – 5:00 p.m. | Day 1 Closing  
  - Dominique Lessard, PhD, Chief Science Officer – KIF1A.ORG |
## 2021 KAND Family & Scientific Engagement Conference

All times are in Eastern Daylight Time, New York City, UTC-04:00

### Saturday, July 10

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 1:00 – 1:05 p.m. | Welcome to Day Two  
• Kathryn Atchley, President, KIF1A.ORG                                                        |
| 1:05 – 1:35 p.m. | Care Guidelines: What We Have & What We Need  
• Wendy Chung, MD, PhD, Chief of Clinical Genetics Division in Pediatrics & Principal Investigator – Columbia University Irving Medical Center  
• Shannon Dennis, DNP, Chief Patient Officer – KIF1A.ORG                                               |
| 1:35 – 1:45 p.m. | Break & Networking                                                                              |
| 1:45 – 2:45 p.m. | KAND Symptoms Q&A  
• Wendy Chung, MD, PhD, Chief of Clinical Genetics Division in Pediatrics & Principal Investigator – Columbia University Irving Medical Center  
• Lia Boyle, MD, PhD Candidate, Researcher, Chung Lab – Columbia University Irving Medical Center  
• Jennifer Bain, MD, PhD, Assistant Professor of Neurology – Columbia University Irving Medical Center  
• Moderated by: Shannon Dennis, DNP, Chief Patient Officer – KIF1A.ORG                                   |
| 2:45 – 2:50 p.m. | Treatment Accelerator Program (TAP) Update  
• Dominique Lessard, PhD, Chief Science Officer – KIF1A.ORG                                            |
| 2:50 – 3:00 p.m. | Introducing Good Dogg Beverage  
• Luke Rosen, Co-Founder & Board Chair – KIF1A.ORG  
• Andrew Parry, Director, Marketing and Communications – Good Dogg Beverage                                |
| 3:00 – 3:45 p.m. | Break & Networking                                                                              |

Before the KAND Conference, view recorded presentations with updates from our therapeutic development collaborators. During the next hour, collaborators will take questions from the audience, moderated by Luke Rosen.

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 3:45 – 4:00 p.m. | Rarebase Update Q&A  
• Omid Karkouti, MS, Co-Founder & COO – Rarebase                                                  |
| 4:00 – 4:15 p.m. | Ovid Therapeutics Update Q&A  
• Patrick Sarmiere, PhD, Senior Director, Molecular Pharmacology – Ovid Therapeutics             |
| 4:15 – 4:30 p.m. | BioLoomics Update Q&A  
• Douglas Chapnick, PhD, CEO & Founder – BioLoomics                                               |
| 4:30 – 4:45 p.m. | Murdoch Children’s Research Institute Update Q&A  
• Simran Kaur, PhD, Research Officer & Research Fellow – Murdoch Children’s Research Institute |
| 4:45 – 5:00 p.m. | Closing Remarks  
• Kathryn Atchley, President – KIF1A.ORG                                                          |
| 5:00 – 5:30 p.m. | Networking                                                                                  |